Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 1,810,000 shares, an increase of 14.6% from the May 31st total of 1,580,000 shares. Approximately 3.7% of the company’s shares are short sold. Based on an average daily volume of 332,700 shares, the short-interest ratio is currently 5.4 days.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Bank of America increased their price objective on shares of Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 13th. Morgan Stanley started coverage on Enfusion in a report on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Enfusion has a consensus rating of “Hold” and an average price target of $9.33.

Enfusion Stock Performance

Shares of Enfusion stock traded up $0.06 on Wednesday, reaching $8.48. 26,985 shares of the company were exchanged, compared to its average volume of 376,468. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 280.93, a P/E/G ratio of 1.98 and a beta of 0.92. Enfusion has a 1-year low of $7.52 and a 1-year high of $11.56. The company’s 50-day moving average is $9.04 and its two-hundred day moving average is $9.03.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $48.05 million during the quarter, compared to analyst estimates of $47.67 million. Enfusion had a return on equity of 6.60% and a net margin of 1.40%. During the same period last year, the business earned $0.04 EPS. As a group, sell-side analysts forecast that Enfusion will post 0.09 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Deirdre Somers sold 4,629 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $8.40, for a total transaction of $38,883.60. Following the sale, the director now owns 43,312 shares in the company, valued at $363,820.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Enfusion news, Director Deirdre Somers sold 4,629 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $8.40, for a total value of $38,883.60. Following the sale, the director now directly owns 43,312 shares of the company’s stock, valued at approximately $363,820.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $8.11, for a total value of $147,934.51. Following the completion of the sale, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The disclosure for this sale can be found here. Insiders have sold 36,318 shares of company stock valued at $296,688 in the last ninety days. Insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Institutional investors have recently bought and sold shares of the stock. Brown Capital Management LLC boosted its stake in Enfusion by 6.5% during the 4th quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after purchasing an additional 724,502 shares in the last quarter. Vanguard Group Inc. boosted its stake in Enfusion by 1.4% during the first quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock valued at $33,792,000 after buying an additional 51,670 shares in the last quarter. Wasatch Advisors LP grew its holdings in Enfusion by 34.2% during the first quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock worth $7,327,000 after acquiring an additional 201,771 shares during the period. Wellington Management Group LLP raised its position in Enfusion by 5.7% in the fourth quarter. Wellington Management Group LLP now owns 489,364 shares of the company’s stock worth $4,747,000 after acquiring an additional 26,464 shares in the last quarter. Finally, Hudson Bay Capital Management LP raised its position in Enfusion by 29.7% in the third quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock worth $4,127,000 after acquiring an additional 105,236 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.